SPRY · ARS Pharmaceuticals, Inc.
$5.93
-0.07 (-1.17%)
At close · Jul 24
Market Cap
$589.86M
Shares
99.30M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$84.28M
-5.5%
FY2025
Net Income
-$171.3M
-2241.8%
FY2025
Gross Margin
100%
FY2023
Operating Margin
-212.92%
-209.5pp
FY2025
Diluted EPS
-$1.74
-2275%
FY2025
Operating Cash Flow
-$170.87M
-1361.2%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| $98.99M | $84.28M | $89.15M | $30K | $1.32M | $5.51M | — | |
| $1.56M | — | — | — | — | $106K | -$29K | |
| — | — | — | $0 | — | — | — | |
| — | — | — | $30K | — | — | — | |
| — | — | — | 100% | — | — | — | |
| $14.57M | $13.18M | $19.58M | $20.27M | $18.38M | $20.27M | $24.58M | |
| $38.7M | — | — | $47.28M | $18.46M | $4.69M | $8.34M | |
| $261.22M | $230.12M | $71.68M | $47.28M | $603K | — | — | |
| $1M | $800K | $100K | — | — | — | — | |
| — | $1.37M | $79K | $100K | $319K | $213K | — | |
| $301.4M | $263.73M | $92.23M | $67.55M | $36.83M | $24.96M | $32.92M | |
| -$202.42M | -$179.45M | -$3.08M | -$67.52M | -$35.52M | -$19.45M | -$32.92M | |
| — | -212.92% | -3.46% | -225066.67% | -2698.78% | -353.32% | — | |
| — | -$178.08M | -$3M | -$67.42M | -$35.2M | -$19.24M | — | |
| $4.36M | $8.07M | $11.37M | $13.16M | $834K | -$789K | — | |
| — | — | — | $0 | -$140K | $0 | — | |
| — | -$171.38M | $8.29M | -$54.37M | — | — | — | |
| — | -$80K | $288K | $0 | $0 | $0 | $0 | |
| -$197.98M | -$171.3M | $8M | -$54.37M | -$34.68M | -$20.24M | -$32.95M | |
| — | -203.25% | 8.97% | -181216.67% | -2635.41% | -367.65% | — | |
| -$198.14M | -$171.39M | $8.17M | -$54.72M | -$34.28M | -$20.24M | -$32.95M | |
| USD/shares | — | -$1.74 | $0.08 | -$0.57 | -$0.87 | -$0.70 | — |
| USD/shares | — | -$1.74 | $0.08 | -$0.57 | -$0.87 | -$0.70 | — |
| shares | — | 98.57M | 96.94M | 95.22M | 39.96M | 28.87M | 2.91M |
| shares | — | 98.57M | 102.39M | 95.22M | 39.96M | 28.87M | 2.91M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.41×
EV/EBIT
—
Biotechnology median 26.60×
P/E (TTM)
—
Biotechnology median 7.07×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Geography (USD)
| Component | FY2025 | FY2024 |
|---|---|---|
| United States | $72,192,000 | $7,255,000 |
| Non Us | $12,086,000 | $81,894,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Product | $72,192,000 | $7,255,000 | $0 |
| Revenue Under Collaboration Agreements | $9,716,000 | $81,529,000 | $30,000 |
| Revenue Under Supply Agreements | $2,370,000 | $365,000 | $0 |